Jounce Therapeutics (JNCE) with $13 Target Got Analyzed By Raymond James.

June 29, 2018 - By Alice Reed

What Price Target Has Raymond James Given Jounce Therapeutics (JNCE)

Raymond James revealed on 28 June an analysts note that it has begun coverage on Jounce Therapeutics (JNCE) that has $13 target price on JNCE and “Outperform” rating.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Coverage

Total analysts of 7 have positions in Jounce Therapeutics Inc (JNCE) as follows: 3 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 43%. Since March 8, 2018 according to StockzIntelligence Inc Jounce Therapeutics Inc has 9 analyst reports. On Thursday, May 17 the stock has “Market Perform” rating by Wells Fargo. On Monday, June 4 the firm has “Hold” rating given by J.P. Morgan. On Tuesday, June 5 the rating was downgraded by Cowen & Co to “Market Perform”. On Monday, June 4 Robert W. Baird maintained Jounce Therapeutics, Inc. (NASDAQ:JNCE) rating. Robert W. Baird has “Outperform” rating and $20 target. On Monday, June 4 the stock of Jounce Therapeutics, Inc. (NASDAQ:JNCE) has “Neutral” rating given by JP Morgan. On Monday, June 4 the stock of Jounce Therapeutics, Inc. (NASDAQ:JNCE) earned “Market Perform” rating by Wells Fargo. On Thursday, March 8 the rating was maintained by Robert W. Baird with “Buy”.

JNCE reached $7.59 during the last trading session after $0.05 change.Currently Jounce Therapeutics, Inc. is downtrending after 49.76% change in last June 29, 2017. JNCE has 99,877 shares volume. JNCE underperformed by 62.33% the S&P 500.

Jounce Therapeutics, Inc. (NASDAQ:JNCE)’s earnings report is expected by WallStreet on August, 8, according to Faxor. earnings per share of $-0.38 is 245.45 % down from 2017’s $-0.11 EPS. After $-0.40 earnings per share was revealed last quarter, analysts now see EPS growth of -5.00 % for Jounce Therapeutics, Inc..

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer.The company has $246.55 million market cap. The Company’s lead product candidate is JTX-2011, a clinical stage monoclonal antibody that binds to and activates the inducible T cell co-stimulator, a protein on the surface of certain T cells found in solid tumors, which is in Phase I/II clinical trial for the treatment of six tumor types, including head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, melanoma, gastric cancer, and other tumor types identified through its translational science platform.Last it reported negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antagonist antibody for combination therapy.

For more Jounce Therapeutics, Inc. (NASDAQ:JNCE) news published briefly go to:,,, or The titles are as follows: “Jounce: Sifting Through The Wreckage” published on June 04, 2018, “Investor Expectations to Drive Momentum within Core-Mark Holding, SSR Mining, iRhythm Technologies, Magic …” on June 06, 2018, “ASCO Conference Preview: Here’s What Biotech Investors Need to Watch” with a publish date: May 31, 2018, “Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients …” and the last “Agios Pharmaceuticals, Inc.Stock Is an Analyst Darling for Good Reason” with publication date: June 05, 2018.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.